2 completed, 1 recruiting, 1 terminated, 1 unknown. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow COPD Exacerbation Acute: new trials by email Literature Review of COPD Exacerbation Acute trials Research Report on COPD Exacerbation Acute
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rademikibart IV for Acute Asthma and COPD Exacerbation Rademikibart - Asthma Acute, COPD Exacerbation Acute | Phase 2 | Recruiting | Connect Biopharm LLC | 40 | 2026-08-21 | 2026-11-04 |
| RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Vapendavir, Placebo - COPD Exacerbation Acute, COPD With Acute Lower Respiratory Infection | Phase 2 | Completed | Altesa Biosciences, Inc. | 52 | 2023-11-20 | 2025-09-30 |
| Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention CUVITRU - Ig subcutaneous human 20%, Standard Medical Therapy - COPD Exacerbation Acute | Phase 2 | Unknown | Rochester General Hospital | 40 | 2023-06-01 | 2023-06-15 |
| Treatment of Pneumocystis in COPD (the TOPIC Study) Trimethoprim Sulfamethoxazole, Placebo - COPD Exacerbation Acute | Phase 1 / Phase 2 | Terminated | Corewell Health East | 1 | 2022-09-28 | 2023-11-29 |
| Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD Beta-Lactams, Fluoroquinolone - COPD Exacerbation Acute | Phase 2 / Phase 3 | Completed | Haiphong University of Medicine and Pharmacy | 170 | 2020-01-01 | 2021-05-10 |
Pulmonary Disease, Chronic Obstructive (3) · Asthma (1) · Common Cold (1) · Emphysema (1) · Enterovirus Infections (1) · Infections (1) · Lung Diseases (1) · Lung Diseases, Obstructive (1) · RNA Virus Infections (1) · Respiration Disorders (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Virus Diseases (1)
Chronic Disease (3) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Lung Diseases (2) · Lung Diseases, Obstructive (2) · Respiratory Tract Diseases (2) · Bronchial Diseases (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Picornaviridae Infections (1) · Respiratory Hypersensitivity (1)
Cefixime (1) · Cefotaxime (1) · Ceftazidime (1) · Ceftriaxone (1) · Ciprofloxacin (1) · Ertapenem (1) · Fluoroquinolones (1) · Levofloxacin (1) · Meropenem (1) · Moxifloxacin (1) · Piperacillin, Tazobactam Drug Combination (1) · Solutions (1) · Sugars (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1) · beta-Lactams (1)
Altesa Biosciences, Inc. (1) · Connect Biopharm LLC (1) · Corewell Health East (1) · Haiphong University of Medicine and Pharmacy (1) · Rochester General Hospital (1)
United States (3) · United Kingdom (1) · Vietnam (1)
Matthew Sims, MD, PhD (1) · Onn Min Kon, MD (1) · Phuong TT Nguyen, PhD MD (1) · Syed S Mustafa, MD (1)